Generic Doryx Launched by Mylan

Mylan has launched a generic version of Mayne’s Doryx, a tetracycline antimicrobial for adjunctive therapy for severe acne.

The FDA recently approved Mylan’s supplemental abbreviated new drug application for doxycycline hyclate delayed-release tablets USP, 200 mg. Mylan will also receive 180 days of marketing exclusivity.

The treatment had sales of around $181.8 million for the year ending on March 31, 2016, according to IMS Health.

Patients who are allergic to tetracyclines should not take Doryx, and those who are pregnant or breastfeeding should talk to a physician before starting the treatment.

Pharmacists can remind patients that Doryx may impact the effectiveness of oral contraceptives.

Some potential adverse effects for patients taking tetracyclines include anorexia, nausea, vomiting, diarrhea, rash, sensitivity to sunlight, hives, and anemia.